1. Home
  2. DVS vs BWAY Comparison

DVS vs BWAY Comparison

Compare DVS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DVS

Dolly Varden Silver Corporation

HOLD

Current Price

$4.76

Market Cap

446.5M

Sector

N/A

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$12.49

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVS
BWAY
Founded
2011
2003
Country
Canada
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
446.5M
450.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DVS
BWAY
Price
$4.76
$12.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
1.4M
79.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$314.08
Revenue Next Year
N/A
$23.37
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$7.84
52 Week High
$5.93
$26.63

Technical Indicators

Market Signals
Indicator
DVS
BWAY
Relative Strength Index (RSI) 49.15 22.41
Support Level $4.28 $11.44
Resistance Level $5.03 $17.20
Average True Range (ATR) 0.27 1.40
MACD 0.02 -0.88
Stochastic Oscillator 61.29 5.21

Price Performance

Historical Comparison
DVS
BWAY

About DVS Dolly Varden Silver Corporation

Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: